Get the Daily Brief
Latest Biotech News
Cell‑based and vesicle therapies revive ovarian function after chemo
Two recent regenerative studies report reproducible restoration of ovarian function after cyclophosphamide‑induced damage: one paper shows cell therapy using oxidoreductase mechanisms can...
Novo’s Wegovy pill cleared by FDA — oral GLP‑1 reaches US market
The U.S. Food and Drug Administration approved Novo Nordisk’s oral semaglutide (Wegovy) for chronic weight management and reduction of major cardiovascular events, clearing the first oral GLP‑1...
Pfizer probes fatal event in Hympavzi hemophilia trial — patient death disclosed
Pfizer disclosed a death in a clinical trial of its tissue factor pathway inhibitor (TFPI) antagonist Hympavzi (marstacimab) after a cerebellar infarction followed by cerebral hemorrhage,...
Boehringer inks US pact with White House — $10B investment, TrumpRx participation
Boehringer Ingelheim agreed to invest $10 billion in U.S. operations through 2028 and join the administration’s TrumpRx.gov purchasing platform in a deal aimed at lowering medicine costs for...
Singlera Genomics expands into Europe with Pure Medical distribution deal
Singlera Genomics struck a research and distribution agreement with EU‑based Pure Medical to commercialize its cell‑free DNA methylation assays, including the mTitan and mGuard platforms, across...
Jacobio outlicenses pan‑KRAS program to AstraZeneca — $1.9B potential deal
Jacobio Pharmaceuticals agreed to outlicense ex‑China rights for its phase I pan‑KRAS inhibitor JAB‑23E73 to AstraZeneca in a deal worth up to $1.915 billion, with AstraZeneca responsible for...
Shionogi pays $2.5B for Tanabe’s edaravone rights — ALS portfolio acquired
Shionogi & Co. agreed to acquire global rights to edaravone from Tanabe Pharma for $2.5 billion, securing both oral and IV formulations marketed in the U.S. as Radicava ORS and Radicava I.V. The...
Harbour Biomed inks big‑ticket BMS collaboration — multispecific antibody program
Harbour Biomed closed a year‑end collaboration with Bristol Myers Squibb to develop multispecific antibodies, receiving roughly $90 million up front with potential milestones topping $1 billion....
Aktis files for Hong Kong IPO — aims to fund Lilly‑partnered radiopharma pipeline
Radiopharmaceutical developer Aktis Oncology filed for an IPO in Hong Kong to raise capital for its miniprotein radioconjugate pipeline, flagging a partnership with Eli Lilly and prior investments...
Signatera MRD readout validates ctDNA as a treatment selector — IMvigor011 impact
The Phase III IMvigor011 trial used Natera’s tumor‑informed Signatera test to select muscle‑invasive bladder cancer patients for adjuvant atezolizumab and reported a clinically meaningful survival...
CMS proposes mandatory Medicare drug demos — pilots would tie U.S. prices to peer nations
The Centers for Medicare & Medicaid Services proposed two mandatory payment demonstration programs that would test most‑favored‑nation‑style pricing for Medicare Parts B and D drugs by aligning...
Wegovy pill approved — First oral GLP‑1 cleared for obesity
The FDA approved Novo Nordisk’s once‑daily oral formulation of semaglutide (Wegovy) for weight management and cardiovascular risk reduction. The decision formalizes trial results showing up to...
Singlera inks EU pact: Pure Medical to distribute cfDNA cancer assays
Singlera Genomics signed a research and distribution agreement with Pure Medical to commercialize its mTitan and mGuard cell‑free DNA (cfDNA) methylation sequencing assays across several European...
AstraZeneca bets on pan‑KRAS — $1.9B Jacobio pact
Jacobio Pharmaceuticals outlicensed its phase I pan‑KRAS inhibitor JAB‑23E73 to AstraZeneca in a deal worth up to $1.915 billion; AstraZeneca paid $100 million upfront and will handle development...
Pfizer probe after trial death — Hympavzi extension under scrutiny
Pfizer disclosed a participant fatality in a long‑term extension trial of its tissue factor pathway inhibitor antagonist Hympavzi (marstacimab), reporting a cerebellar infarction followed by...
Patient deaths halt lung ADC Phase III recruitment
Daiichi Sankyo placed a partial hold on recruitment and enrollment in the phase III IDeate‑Lung02 study of the antibody‑drug conjugate ifinatamab deruxtecan after an unexpected rise in grade 5...
Harbour Biomed inks BMS multispecifics deal — $90M now, $1B+ later
Harbour Biomed closed a year‑end collaboration with Bristol Myers Squibb to develop multispecific antibodies, receiving roughly $90 million up front and potential milestones that could exceed $1...
Boehringer joins TrumpRx — $10B US investment and pricing pact
Boehringer Ingelheim struck an agreement with the U.S. administration to join the TrumpRx.gov purchasing platform and pledged $10 billion in U.S. investments through 2028 to expand R&D and...
Aktis files for IPO — radiopharma firm seeks capital for Lilly partnership
Aktis Oncology filed for an initial public offering to fund a pipeline of radiopharmaceutical candidates and to expand operations for its Lilly‑partnered programs. The company plans to...
MRD testing reaches inflection — Signatera trial yields randomized evidence
Minimal residual disease (MRD) testing advanced to clinical decision‑making in 2025 as Phase III and other randomized readouts validated ctDNA‑guided treatment strategies. The Phase III IMvigor011...